Menu Search
Equities

Tempest Therapeutics Inc

3OS:BER

Tempest Therapeutics Inc

Actions
  • Price (EUR)0.8715
  • Today's Change-0.005 / -0.63%
  • Shares traded1.00k
  • 1 Year change-75.93%
  • Beta--
Data delayed at least 15 minutes, as of Nov 25 2024 14:36 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

  • Revenue in USD (TTM)0.00
  • Net income in USD-35.52m
  • Incorporated2011
  • Employees17.00
  • Location
    Tempest Therapeutics Inc2000 SIERRA POINT PARKWAY, SUITE 400BRISBANE 94005United StatesUSA
  • Phone+1 (415) 798-8589
  • Fax+1 (302) 655-5049
  • Websitehttps://www.tempesttx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.